The Study of Efficacy of Chemotherapy Combined with Targeted Drug Therapy in Patients with Advanced Non-small Cell Lung Cancer

Abstract

Abstract: Objective To study the efficacy of chemotherapy combined with targeted drug therapy in patients with advanced non-small cell lung cancer （NSCLC）. Methods A total of 80 patients with NSCLC who were admitted and treated in Sinopharm North Hospital from October 2019 to October 2020 were selected. They were randomly divided into two groups, the observation group and the control group.The control group received chemotherapy, while the observation group received chemotherapy combined with targeted drug therapy. The the prognosis of NSCLC patients in the two groups were compared, including treatment effect and adverse reactions, quality of life and lung function. Results The European Organization for Research and Treatment of Cancer （EORTC QLQ-C30） score in the observation group was significantly higher than that in the control group （P<0.05）. The forced vital capacity （FVC） and forced expiratory volume in one second （FEV₁） of patients in the observation group were significantly higher than those in the control group （P<0.05）. The total effective rate in the observation group was significantly higher than that in the control group （P<0.05）; the incidences of adverse reactions such as nausea, vomiting, rash, diarrhea, and bone marrow suppression in the observation group were significantly less than those in the observation group were significantly lower than those in the control group （P<0.05）. Conclusion Chemotherapy combined with targeted drugscould improve the clinical efficacy and lung function of NSCLC patients, while improving the quality of life of patients, with high safety.

Key words: non-small cell lung cancer, chemotherapy, targeted drug therapy, clinical efficacy, adverse reactions

CLC Number:

R734.2

XIN Hong-mei, BAO Yong-jian. The Study of Efficacy of Chemotherapy Combined with Targeted Drug Therapy in Patients with Advanced Non-small Cell Lung Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(10): 18-20.

References

[1] 葛凤娟. 常规化疗联合靶向药物吉非替尼治疗晚期非小细胞肺癌患者的临床疗效[J].中华养生保健,2021,39(15):143-144.
[2] 范彦博,汪睿.榄香烯注射液联合化疗与靶向药物对晚期非小细胞肺癌患者生活质量、免疫功能的影响[J].世界中西医结合杂志,2021, 16(1):119-122,127.
[3] 徐燕,田春香,刘武,等.化疗序贯靶向药物治疗表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药老年晚期非小细胞肺癌患者临床研究[J].肿瘤研究与临床,2018,30(9):617-620.
[4] 陈华林,杨东红,罗怡平,等.埃克替尼联合化疗治疗EGFR突变型晚期非小细胞肺癌的疗效及对生活质量和血清肿瘤标志物的影响[J].现代生物医学进展,2021,21(6):1138-1142.
[5] 许子宜,李峻岭.免疫检查点抑制剂联合抗血管生成药物治疗晚期非鳞状细胞非小细胞肺癌的研究进展[J].癌症进展,2019,17(18):2109-2113.
[6] 张繁霜,邱田,应建明.基于TCGA数据库对NCCN指南中相关基因在肺腺癌中突变频率的分析[C].//2019中国肿瘤学大会论文集. 2019: 5559-5560.
[7] 杨熙园,沈雅平,陶晓娜.甲磺酸阿帕替尼片联合支气管动脉灌注化疗栓塞术治疗中晚期非小细胞肺癌的临床研究[J].医学食疗与健康,2019(17):4-5.
[8] 翟素平,黄秀红,马昕炜.血清CEA、CA125水平在靶向药物治疗非小细胞肺癌的疗效预测中的价值[J].实验与检验医学,2021,39(3):697-699,709.
[9] 刘舒婷,赵大海.晚期非小细胞肺癌患者靶向药物(埃克替尼)耐药后再选择的分析[J].临床肺科杂志,2018,23(3):406-410.
[10] 王伟英,董良,李海金,等.安罗替尼联合化疗二线治疗酪氨酸激酶抑制剂获得性耐药晚期非小细胞肺癌临床观察[J].中华肿瘤防治杂志,2020,27(20):1669-1673.
[11] 肖霞,王琦,过雪丹,等.表皮生长因子受体突变晚期非小细胞肺癌靶向治疗效果影响因素分析[J].肿瘤研究与临床,2021,33(1):1-8.
[12] 王鸣,王晶,陈昕,等.表皮生长因子受体酪氨酸激酶抑制剂和化疗治疗晚期非小细胞肺癌的临床疗效比较[J].医学综述,2019, 25(24): 5016-5020,5025.
[13] 张渊,邱丽娟,王镇,等.吉非替尼联合培美曲塞维持治疗晚期非小细胞肺癌的疗效观察[J].现代实用医学,2020,32(1):111-112.
[14] 姜战胜,张宇,任秀宝,等.晚期非小细胞肺癌一线生物靶向治疗的研究进展[J].中国肿瘤生物治疗杂志,2020,27(8):843-851.
[15] 裴晓俊. 甲磺酸阿帕替尼联合吉西他滨+顺铂化疗对晚期非小细胞肺癌患者疾病缓解率及卡氏评分的影响[J].中国药物与临床,2020, 20(8):1349-1351.
[16] 白玉梅,薛丽.贝伐珠单抗联合培美曲塞/顺铂治疗晚期非鳞非小细胞肺癌疗效及安全性观察[J].实用医技杂志,2019,26(4):484-486.
[17] 张宁. 化疗联合靶向药物治疗晚期非小细胞肺癌的效果观察[J].航空航天医学杂志,2021,32(6):690-691.
[18] 刘林. 一线应用靶向药物联合常规化疗治疗晚期非小细胞肺癌的临床观察分析[J].中国医药指南,2018,16(10):86-87.